Nanomedicine News RSS Feed - Nanomedicine

UCI Receives NSF Grant to Further Develop Nano-Optical Sensor for Detecting Infection in Breath

UCI Receives NSF Grant to Further Develop Nano-Optical Sensor for Detecting Infection in Breath

Imagine a low-cost, disposable breath analysis device that a person with cystic fibrosis could use at home along with a smartphone to immediately detect a lung infection, much like the device police use to gauge a driver's blood alcohol level. [More]
Alnylam Presents Clinical Data for Patisiran Phase II OLE Study for Familial Amyloidotic Polyneuropathy

Alnylam Presents Clinical Data for Patisiran Phase II OLE Study for Familial Amyloidotic Polyneuropathy

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP). [More]
Nanosphere Receives FDA 510(k) Clearance for Verigene Enteric Pathogens Nucleic Acid Test

Nanosphere Receives FDA 510(k) Clearance for Verigene Enteric Pathogens Nucleic Acid Test

Nanosphere, Inc., a company enhancing medicine through targeted molecular diagnostics, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Verigene® Enteric Pathogens Nucleic Acid Test (EP), which now includes additional viral targets, as well as the bacterial and toxigenic targets cleared by FDA earlier this summer. [More]
Nanoscale DNA Cocoons Target Cancer Cells

Nanoscale DNA Cocoons Target Cancer Cells

Biomedical engineering researchers have developed a drug delivery system consisting of nanoscale “cocoons” made of DNA that target cancer cells and trick the cells into absorbing the cocoon before unleashing anticancer drugs. The work was done by researchers at North Carolina State University and the University of North Carolina at Chapel Hill. [More]
Onxeo Receives Second Payment from BPIFrance for Support of Nano Innovation for Cancer Consortium

Onxeo Receives Second Payment from BPIFrance for Support of Nano Innovation for Cancer Consortium

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, today announces the second payment of €1.25 million from BPIFrance (ex OSEO) as a part of the funding granted to support the NICE (Nano Innovation for Cancer) consortium. [More]
Scientists Identify Key Characteristics That Enhance Nanoparticle’s Ability to Penetrate Skin

Scientists Identify Key Characteristics That Enhance Nanoparticle’s Ability to Penetrate Skin

Scientists at the University of Southampton have identified key characteristics that enhance a nanoparticle's ability to penetrate skin, in a milestone study which could have major implications for the delivery of drugs. [More]
Aciex Awarded US Patent for Novel Nanocrystalline Formulations of Fluticasone Propionate

Aciex Awarded US Patent for Novel Nanocrystalline Formulations of Fluticasone Propionate

Aciex Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. Patent (No. 8,829,005) covering AC-170 Cetirizine Ophthalmic Compositions and a U.S. Patent (No. 8,765,725) covering AC-155 Fluticasone Propionate Nano-crystalline Compositions. [More]
MJR PharmJet Wins Award for Technology That Enables Increased Drug Loading of Hydrophobic Nanoparticles

MJR PharmJet Wins Award for Technology That Enables Increased Drug Loading of Hydrophobic Nanoparticles

CPhI Worldwide, organised by UBM Live, announced the winners of the 11th annual CPhI live Pharma Awards. The annual awards showcase outstanding developments and innovations from the pharma industry's most dynamic and progressive players. [More]
MHTX’s MRX Technology Holds Promise for Early Detection of Ovarian Cancer

MHTX’s MRX Technology Holds Promise for Early Detection of Ovarian Cancer

Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc., is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea. [More]
Nanoparticle Topical Solution to Combat Dry Eye Syndrome

Nanoparticle Topical Solution to Combat Dry Eye Syndrome

For the millions of sufferers of dry eye syndrome, their only recourse to easing the painful condition is to use drug-laced eye drops three times a day. Now, researchers from the University of Waterloo have developed a topical solution containing nanoparticles that will combat dry eye syndrome with only one application a week. [More]